Meridian Bioscience Performance dei guadagni passati

Il passato criteri di controllo 1/6

Meridian Bioscience ha registrato una crescita degli utili a un tasso medio annuo di 25.3%, mentre il settore Medical Equipment ha registrato utili in crescita a un tasso medio annuo di 12%. I ricavi sono stati in crescita a un tasso medio annuo di 13%. Il ritorno sul capitale proprio di Meridian Bioscience è 11.5% e ha margini netti di 12.7%.

Informazioni chiave

25.3%

Tasso di crescita degli utili

24.7%

Tasso di crescita dell'EPS

Medical Equipment Crescita del settore	8.9%
Tasso di crescita dei ricavi	13.0%
Rendimento del capitale proprio	11.5%
Margine netto	12.7%
Ultimo aggiornamento sui guadagni	30 Sep 2022

Aggiornamenti sulle prestazioni recenti

Recent updates

Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M

Aug 05

Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital

Jun 09

Meridian Bioscience: Deceptively Priced

Mar 14

Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns

Feb 03

These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely

Jul 19

If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy

Jul 08

Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine

May 10

Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation

May 08

Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly

Mar 31

Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?

Mar 11

Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%

Feb 24

Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues

Feb 09

Meridian expands production capacity for COVID-19 tests with NIH funding

Feb 03

Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?

Jan 27

Ripartizione dei ricavi e delle spese

Come Meridian Bioscience guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGS:VIVO Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Sep 22	333	42	88	24
30 Jun 22	344	43	90	24
31 Mar 22	339	62	86	24
31 Dec 21	313	60	80	24
30 Sep 21	318	71	76	24
30 Jun 21	306	71	76	25
31 Mar 21	327	87	76	25
31 Dec 20	299	70	74	25
30 Sep 20	254	46	71	24
30 Jun 20	240	44	68	22
31 Mar 20	204	21	64	20
31 Dec 19	197	19	61	19
30 Sep 19	201	24	62	18
30 Jun 19	203	26	62	16
31 Mar 19	207	27	64	16
31 Dec 18	213	26	68	16
30 Sep 18	214	24	70	17
30 Jun 18	210	24	69	18
31 Mar 18	209	18	68	17
31 Dec 17	206	22	66	17
30 Sep 17	201	22	63	16
30 Jun 17	198	21	63	15
31 Mar 17	199	30	63	15
31 Dec 16	195	30	61	14
30 Sep 16	196	32	59	14
30 Jun 16	195	35	58	13
31 Mar 16	192	36	55	13

Guadagni di qualità: VIVO ha un grande una tantum perdita di $21.2M che ha avuto un impatto sui suoi ultimi 12 mesi di risultati finanziari pari a 30th September, 2022.

Margine di profitto in crescita: Gli attuali margini di profitto netti di VIVO (12.7%) sono inferiori rispetto allo scorso anno (22.5%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di VIVO sono cresciuti in modo significativo del 25.3% all'anno negli ultimi 5 anni.

Accelerare la crescita: VIVO ha avuto una crescita negativa degli utili nell'ultimo anno, quindi non può essere confrontata con la sua media quinquennale.

Guadagni vs Settore: VIVO ha avuto una crescita negativa degli utili ( -40.5% ) nell'ultimo anno, rendendo difficile il confronto con la media del settore Medical Equipment ( 10.4% ).

Meridian Bioscience Performance dei guadagni passati

Il passato criteri di controllo 1/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Meridian Bioscience, Inc. to Report Q4, 2022 Results on Nov 22, 2022

Full year 2022 earnings: EPS exceeds analyst expectations

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings released: EPS US$1.65 (vs US$1.08 in FY 2020)

Third quarter 2021 earnings released: EPS US$0.27 (vs US$0.64 in 3Q 2020)

Recent updates

Meridian Bioscience Leads the Way with Innovative Sustainable Solutions for in Vitro Diagnostic Manufacturers

Meridian Bioscience Unveils Industry-First Lyophilized Library Prep Kit for Next-Generation Sequencing, Eliminating the Need for Cold-Chain Shipping and Storage

Meridian Bioscience, Inc. Drives Democratization of Next-Generation Sequencing with Reagents Enabling Ambient Temperature Shipping and Storage of Sequencing Kits

Meridian Bioscience Continues Expansion of H. Pylori Diagnostic Testing Solutions with Fda Clearance of Premier Hpsa Flex

Meridian Bioscience, Inc. announced that it expects to receive KRW 258.225164381 billion in funding

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others.

Independent Director exercised options to buy US$285k worth of stock.

Meridian Bioscience, Inc. to Report Q4, 2022 Results on Nov 22, 2022

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$34.00

Insufficient new directors

Impactive Capital Provides Information to Shareholders of Meridian Bioscience

Consensus EPS estimates fall by 31%

Meridian Bioscience, Inc. Provides Update on Earnings Guidance for the Fiscal Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M

Meridian Bioscience, Inc. Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

Meridian Bioscience: High-Probability Merger Arbitrage

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners (collectively, the "Consortium") entered into a definitive merger agreement to acquire Meridian Bioscience, Inc. (NasdaqGS:VIVO) for $1.5 billion.

Meridian Bioscience downgraded at William Blair on $1.53B acquisition

Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet

Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from Russell 2000 Value-Defensive Index

Meridian Bioscience: Correctly Valued

President exercised options and sold US$1.1m worth of stock

Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays

Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital

Meridian Bioscience, Inc. Responds to the Monkeypox Outbreak with Its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests

Meridian Bioscience, Inc. Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays

Insufficient new directors

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Second Quarter of Fiscal 2022

Meridian Bioscience: Deceptively Priced

Meridian Bioscience, Inc. Names Andy Kitzmiller as Executive Vice President

Magellan Diagnostics Resumes Distribution of Leadcare® II Test Kits

Investor sentiment improved over the past week

Price target increased to US$30.00

Meridian Bioscience, Inc. Raises Earnings Guidance for the Full Fiscal Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns

Meridian Bioscience Launches Lyo-Ready qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection

Meridian Bioscience, Inc. Announces Board Changes

Key Executive exercised options to buy US$157k worth of stock.

Meridian Bioscience, Inc. Receives FDA-Clearance for the Curian® Campy Assay

Full year 2021 earnings released: EPS US$1.65 (vs US$1.08 in FY 2020)

Insufficient new directors

Insufficient new directors

Price target decreased to US$27.00

Meridian Bioscience, Inc. Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples

Price target decreased to US$30.50

Third quarter 2021 earnings released: EPS US$0.27 (vs US$0.64 in 3Q 2020)

These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely

Investor sentiment deteriorated over the past week

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Third Quarter of Fiscal 2021

If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy

Meridian Bioscience, Inc. Announces Launch of the Lyo-Ready RT-LAMP Mix

Meridian Bioscience, Inc. Improves Field-Testing in AgBio with its New Air-Dryable™ qPCR Mix for Crude Plant Samples

Consensus forecasts updated

Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine

Second quarter 2021 earnings released: EPS US$0.61 (vs US$0.22 in 2Q 2020)

Meridian Bioscience, Inc. Provides Revenue Guidance for the Fiscal Year 2021

Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation

Meridian Bioscience, Inc. Announces the Launch of the Lyo-Ready DNA LAMP Mix

Investor sentiment deteriorated over the past week

Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly

President recently sold US$250k worth of stock

Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?

Meridian Bioscience, Inc. Announces the Launch of New Air-Dryable Direct DNA qPCR Blood Mix

Meridian Bioscience Provides A Further Update on the Revogene® Sars-Cov-2 Eua Submission

Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%

Investor sentiment deteriorated over the past week